Context Therapeutics Inc.
CNTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $4 | $0 | $0 | $0 |
| Gross Profit | -$4 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8,722 | $7,831 | $3,463 | $2,518 |
| G&A Expenses | $1,888 | $1,928 | $2,066 | $1,792 |
| SG&A Expenses | $1,888 | $1,928 | $2,066 | $1,792 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,606 | $9,758 | $5,529 | $4,310 |
| Operating Income | -$10,610 | -$9,758 | -$5,529 | -$4,310 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $917 | $931 | $952 | $968 |
| Pre-Tax Income | -$9,693 | -$8,828 | -$4,577 | -$3,343 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9,693 | -$8,828 | -$4,577 | -$3,343 |
| % Margin | – | – | – | – |
| EPS | -0.1 | -0.093 | -0.05 | -0.057 |
| % Growth | -7.9% | -85.4% | 12.6% | – |
| EPS Diluted | -0.1 | -0.093 | -0.05 | -0.057 |
| Weighted Avg Shares Out | 95,185 | 95,187 | 95,187 | 58,416 |
| Weighted Avg Shares Out Dil | 95,185 | 95,187 | 95,187 | 58,416 |
| Supplemental Information | – | – | – | – |
| Interest Income | $834 | $904 | $959 | $964 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $4 | $4 | $3 |
| EBITDA | -$9,689 | -$9,754 | -$5,525 | -$4,307 |
| % Margin | – | – | – | – |